A meta-analysis of numerous large clinical trials has provided robust evidence that Sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly delay the progression of chronic kidney disease (CKD) and reduce cardiovascular events in patients with CKD, regardless of diabetes status [1]. Here, SLC5A2 is linked to diabetes mellitus.